Endo Pops After Parkinson's Tests, IDexx Continues Fall, Biogen Higher: Tuesday's Biotech Movers

Endo Pops After Parkinson's Tests, IDexx Continues Fall, Biogen Higher: Tuesday's Biotech Movers


The FDA approved Spinraza in late December as the first treatment for spinal muscular atrophy , a rare, genetic condition affecting children that causes the loss of motor neurons in the spinal cord and lower brain stem, resulting in progressive loss of muscle function. Spinraza is being looked to as Biogen's new blockbuster as sales for its multiple sclerosis drugs flatten out.



from Biotech News